Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/148484| Title: | Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors : society for perioperative Assessment and quality improvement (SPAQI) multidisciplinary consensus statement. Comment on Br J Anaesth 2026; 136 : 1776–99 |
| Authors: | Rüggeberg, Anne Camilleri Podestà, Anne Marie |
| Keywords: | Diabetes Fasting Patient safety Patients -- Safety measures Hypoglycemic agents Type 2 diabetes -- Treatment Hyperglycemia -- Treatment |
| Issue Date: | 2026 |
| Publisher: | Elsevier Ltd |
| Citation: | Rüggeberg, A., & Camilleri Podestà, A. M. (2026). Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Comment on Br J Anaesth 2026; 136: 1776–99. British Journal of Anaesthesia, 1-3. |
| Abstract: | The recently published multidisciplinary Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement by Oprea and colleagues provides an important step towards weighing up the risks and benefits of perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2i). The well-established benefits of SGLT2is in terms of glycaemic control, cardiovascular morbidity and mortality, and renal function are balanced against the risk of euglycaemic diabetic ketoacidosis (eDKA). |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/148484 |
| Appears in Collections: | Scholarly Works - FacM&SSur |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Perioperative_management_of_patients_taking_sodium-glucose_cotransporter_2_inhibitors_society_for_perioperative_Assessment_and_Quality_Improvement_(SPAQI)(2026).pdf | 480.61 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.